Back to Journals » International Journal of Nanomedicine » Volume 17

Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum]

Authors Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi M, Dinarvand R 

Received 3 October 2022

Accepted for publication 3 October 2022

Published 26 October 2022 Volume 2022:17 Pages 5047—5048

DOI https://doi.org/10.2147/IJN.S392079



Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi M, Dinarvand R. Int J Nanomedicine. 2011;6:1977—1990.

The authors have advised Figure 9D on page 1986 is incorrect. Due to an error at the time of figure assembly Figure 9B and D were duplicated. The correct Figure 9 is shown below.

Figure 9 Fluorescence microscopy of cellular uptake of (A) trastuzumab-decorated chitosan-doxorubicin conjugated nanoparticles by SKOV-3 cell line, (B) trastuzumab-decorated chitosan-doxorubicin conjugated nanoparticles by MCF-7 cell line, (C) chitosan-doxorubicin conjugated nanoparticles by SKOV-3 cell line, and (D) chitosan-doxorubicin conjugated nanoparticles by MCF-7 cell line. (E) SKOV-3 cells and (F) MCF-7 cells in cell culture medium served as negative controls.

The authors previously requested a corrigendum to correct this error soon after publication but it was not actioned due to communication issues between the journal and authors. The authors have now contacted the journal again several years later to request the same corrigendum in relation to the same error. The authors apologize for the error and advise it does not affect the results of the paper.


Read the original article


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.